Key Highlights
- India’s Sun Pharmaceutical Industries has reached an agreement to acquire Organon & Co through an all-cash transaction that values the firm at $11.75 billion, debt included.
- Shareholders of Organon will be paid $14.00 in cash for each share they hold.
- Shares of Organon jumped approximately 31% last Friday following initial media reports, then added another ~15% during Monday’s premarket session.
- When merged, the new pharmaceutical entity would secure a position within the world’s top 25 pharma companies, boasting pro forma revenues of $12.4 billion.
- Subject to regulatory clearances and shareholder consent, the transaction is anticipated to finalize in early 2027.
India’s leading pharmaceutical manufacturer, Sun Pharma, revealed on Sunday its intention to purchase New Jersey-headquartered Organon & Co in a complete cash transaction valued at $11.75 billion when accounting for debt obligations. Each share will be purchased at $14.00.
Shares of Organon had already experienced a dramatic rally of nearly 31% last Friday when the Economic Times initially broke news that Sun Pharma was negotiating to purchase the company for approximately $13 billion. Following Sunday’s official confirmation of terms, Organon shares climbed an additional ~15% during early Monday premarket activity.
Organon & Co., OGN
Combined across both trading sessions, the pharmaceutical stock has rallied approximately 46% from its pre-announcement trading levels.
Organon emerged as an independent company through a 2021 spinoff from Merck and specializes in women’s healthcare products, biosimilar medications, and established brand-name pharmaceuticals. The company generated $6.2 billion in revenue and posted adjusted EBITDA of $1.9 billion throughout 2025.
Sun Pharma disclosed that acquisition financing will come from a combination of available cash reserves and secured banking facilities. The transaction has received unanimous approval from both companies’ boards of directors.
Strategic Benefits for Sun Pharma
This acquisition provides Sun Pharma with immediate access to a diverse portfolio exceeding 70 pharmaceutical products distributed throughout more than 140 nations worldwide. The deal also establishes the Indian pharmaceutical company’s presence in the biosimilars market, where the merged organization would rank as the seventh-largest competitor globally.
Organon maintains strong commercial presence across the United States, European markets, China, Canada, and Brazil. The company controls six production facilities strategically located throughout the European Union and developing markets.
Macquarie analyst Dr. Kunal described the acquisition as “strategically and financially compelling” for Sun. He highlighted that the merged organization will derive 27% of revenues from innovative pharmaceutical products, representing an increase from Sun Pharma’s current 20% exposure.
Sun Pharma currently maintains focused operations in dermatology, ophthalmology, and onco-dermatology within the innovative medicines segment. Incorporating Organon’s comprehensive women’s health product lineup would substantially broaden that therapeutic reach.
The consolidated pharmaceutical company would also establish itself as a top-three competitor in the global women’s healthcare sector.
Financial Leverage Considerations
Organon entered this transaction carrying a significant debt burden of $8.6 billion against cash reserves of $574 million as of December 2025. The company’s net debt to EBITDA multiple was positioned at 4 times prior to the deal announcement.
Sun Pharma, in contrast, maintained a net cash positive balance sheet before announcing this acquisition. Following transaction completion, analysts project the combined organization will operate with a net debt to EBITDA ratio of 2.3 times.
Bhavesh Shah of Equirus Capital observed that acquisitions of this magnitude can prove “value accretive over the medium to long term,” though he cautioned about short-term headwinds including integration expenses and operational execution risks.
This marks the sixth major acquisition Sun Pharma has completed over the past 16 years. Previous transactions include the 2007 purchase of financially distressed Israeli pharmaceutical company Taro Pharma and the 2014 acquisition of Ranbaxy Laboratories for approximately $3.2 billion.
The Organon acquisition is projected to elevate Sun Pharma into the ranks of the world’s 25 largest pharmaceutical corporations, with the combined organization generating pro forma revenues of $12.4 billion.
Subject to obtaining necessary regulatory approvals and shareholder authorizations, the transaction is scheduled to reach completion in early 2027.
The post Sun Pharma’s $11.75B Acquisition Sends Organon (OGN) Stock Soaring 46% appeared first on Blockonomi.
Source: https://blockonomi.com/sun-pharmas-11-75b-acquisition-sends-organon-ogn-stock-soaring-46/